Drug Patents owned by Rigel Pharms Inc
1. List of Rezlidhia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10550098 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US10414752 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US11498913 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(16 years from now) | |
| US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(16 years from now) | |
| US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(16 years from now) | |
| US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(16 years from now) | |
| US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 1, 2027 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 2026-12-01
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...
Dosage: CAPSULE;ORAL
REZLIDHIA family patents
56
United States
6
European Union
5
Australia
4
Mexico
4
Morocco
4
Spain
3
Israel
3
Japan
3
Canada
2
Denmark
2
Slovenia
2
Lithuania
2
Croatia
2
Portugal
2
Poland
2
RS
2
China
2
EA
1
South Africa
1
Saudi Arabia
1
Hungary
1
Philippines
1
Argentina
1
Singapore
1
Brazil
1
Colombia
1
Cyprus
1
Malaysia
1
Peru
1
Korea, Republic of
1
Chile
1
Taiwan, Province of China
1
Ecuador
1
New Zealand
1
ME
2. List of Tavalisse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8211889 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
| US7538108 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(2 years from now) | |
| US7989448 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8163902 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US7449458 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266912 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
| USRE48898 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
| US9283238 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8912170 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8445485 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(3 years from now) | |
| US8652492 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2028
(5 years from now) | |
| US8263122 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2030
(7 years from now) | |
| US8771648 | RIGEL PHARMS INC | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(9 years from now) | |
| US8951504 | RIGEL PHARMS INC | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 17, 2025 |
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2023 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 2022-04-17
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
TAVALISSE family patents
34
United States
6
European Union
5
Korea, Republic of
5
Japan
4
Denmark
4
Mexico
4
Spain
4
Canada
3
Australia
3
Hong Kong
3
Lithuania
3
Slovenia
3
Hungary
3
Brazil
3
Portugal
3
Poland
3
China
2
Israel
2
Austria
2
Turkey
2
Norway
2
Croatia
2
Cyprus
2
RS
2
Ukraine
2
EA
2
New Zealand
1
South Africa
1
Russia
1
Uruguay
1
Cuba
1
Costa Rica
1
Germany
1
Argentina
1
Colombia
1
Singapore
1
Honduras
1
Malaysia
1
Netherlands
1
Dominican Republic
1
United Kingdom
1
Luxembourg
1
Nicaragua
1
Ecuador
1
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic